Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234536 | 0.82 | NPC1 (0.37) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL19862530 | 0.82 | NPC1 (0.37) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL20909675 | 0.80 | NPC1 (0.35) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL22733836 | 0.80 | CYP2A6 (0.36) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL12161061 | 0.77 | NPC1 (0.37) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL13868022 | 0.77 | RIPK1 (0.39) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL11539034 | 0.77 | GSK3B (0.38) | PKMNPC1RAB9AGSK3BRIPK1 | |
| SCHEMBL23328657 | 0.75 | — | — | |
| SCHEMBL9577296 | 0.75 | GSK3B (0.37) | PKMNPC1RAB9AATML3MBTL1 | |
| SCHEMBL16254998 | 0.75 | NPC1 (0.36) | PKMNPC1RAB9AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230165813-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-06-01 | — | — | US | disclosed |
| US-20230165813-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-06-01 | — | — | US | disclosed |
| US-20230143449-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230020526-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070219246-A1 | Dihydrobenzothiophenes | MERCK PATENT GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007009717-A1 | PYRAZOLE-4- CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | PKM 3599/4885NPC1 490/4885RAB9A 2683/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | PKM 3517/4885NPC1 723/4885RAB9A 1377/4885 |
| US-20230020526-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | RO60, RPS10, SOD1 | PKM 2843/4885NPC1 4794/4885RAB9A 698/4885 |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | PKM 3069/4885NPC1 4/4885RAB9A 4606/4885 |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | CD14, FPR1, FPR2 | PKM 1570/4885NPC1 1037/4885RAB9A 2152/4885 |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | PKM 1249/4885NPC1 2532/4885RAB9A 1372/4885 |
| US-20230143449-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OXER1 | PKM 1702/4885NPC1 2645/4885RAB9A 1432/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | PKM 3290/4885NPC1 2355/4885RAB9A 2598/4885 |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ABL1, MCL1, ABL2 | PKM 1036/4885NPC1 2652/4885RAB9A 1621/4885 |
| US-20070219246-A1 | Dihydrobenzothiophenes | CCNT1, CCNT2, TPT1 | PKM 3618/4885NPC1 3392/4885RAB9A 2614/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | PKM 2458/4885NPC1 4479/4885RAB9A 2572/4885 |
| US-20230165813-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF | HDAC6, HDAC9, HDAC5 | PKM 1892/4885NPC1 1858/4885RAB9A 1838/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | PKM 2859/4885NPC1 4221/4885RAB9A 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.